A phase I study combining nivolumab (Opdivo) with nab-paclitaxel (Abraxane) and gemcitabine demonstrated that the combination is feasible and the antitumor activity of this regimen appears to be encouraging for patients with advanced pancreatic cancer. Read more . . .
There are several novel therapeutic approaches under investigation for the treatment of patients with pancreatic cancer. Immunotherapy, for example, has become an area of excitement, with early combination studies showing activity in these tumors.